Figure 3.

Baseline tumor IL1RAP expression is associated with deeper and more durable response to nadunolimab and GN. Screening biopsies, archival or study specific, were collected from 49 patients and stained for IL1RAP by IHC. A, Representative images are shown of IL1RAP-positive tumor cells (left), cancer-associated fibroblasts (center), and infiltrating immune cells (right). B, Tumor cell expression of IL1RAP was quantified by H-score and the distribution plotted; IL1RAP high was defined as ≥150 and IL1RAP low as <150. Representative images of tumor sections with low and high IL1RAP H-score are shown. C, The correlation between IL1RAP expression and OS was analyzed with a Kaplan–Meier analysis and IL1RAP-high and IL1RAP-low subgroups compared using the log-rank test. D, Clinical responses in the IL1RAP-high and IL1RAP-low groups were visualized in a waterfall (top) and a swimmer plot (bottom). iCPD, immune confirmed progressive disease; iPR, immune partial response; iSD, immune stable disease; iUPD, immune unconfirmed progressive disease.